Animal health firm ImmuCell Q3 sales fall 8%, hurt by previous production interruptions

ImmuCell

13/11/2025 21:34

Overview

ImmuCell Q3 2025 product sales decreased by 8% yr/yr to $5.5 mln

Company reported a net loss of $140,000 for Q3 2025

Gross margin improved to 43% in Q3 2025 from 26% in Q3 2024

Outlook

Company continues to collect market feedback on Re-Tain through 2026

ImmuCell has sufficient inventory to drive product adoption and revenue growth

Result Drivers

BACKLOG IMPACT - Previous production interruptions led to backlog issues affecting Q3 sales, per CFO Timothy C. Fiori

GROSS MARGIN RECOVERY - Gross margin improved to 43% in Q3 2025 due to higher product sales and cost control, per CFO Timothy C. Fiori

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Product Sales
$5.51 mln
Q3 EPS
-$0.02
Q3 Net Income
-$140,000
Q3 Basic EPS
-$0.02
Q3 Operating Expenses
$2.34 mln
Q3 Pretax Profit
-$135,000


Press Release: ID:nGNX72YcGF

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)